EMEA-002030-PIP01-16
Key facts
| Active substance |
ambrisentan
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0038/2017
|
| PIP number |
EMEA-002030-PIP01-16
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of pulmonary arterial hypertension
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Glaxo Group Limited
United Kingdom |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|